You are here

  • Home
  • Archive
  • Volume 71, Issue Suppl 3
  • OP0205 Efficacy and safety evaluation of iguratimod, a novel anti-rheumatic agent – a double-blind, comparative study of iguratimod-MTX combination in rheumatoid arthritis patients with an inadequate response to MTX

Article info

Article menu
Download PDFPDF
Scientific Abstracts
Oral Presentations
Abstract Session: Molecules – small and smart
OP0205 Efficacy and safety evaluation of iguratimod, a novel anti-rheumatic agent – a double-blind, comparative study of iguratimod-MTX combination in rheumatoid arthritis patients with an inadequate response to MTX

Authors

Citation

Hara M, Ishiguro N, Katayama K, et al
OP0205 Efficacy and safety evaluation of iguratimod, a novel anti-rheumatic agent – a double-blind, comparative study of iguratimod-MTX combination in rheumatoid arthritis patients with an inadequate response to MTX
Annals of the Rheumatic Diseases 2013;71:124-125.

Publication history

  • First published January 23, 2014.
Online issue publication 
April 13, 2016

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions